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were included in the new work ﬂow. A list of disease-
speciﬁc staging was developed to guide disease status at
annual evaluations. A visual approach was created in the
spreadsheet to track forms completion with all patients
due dates as follows: green - form may be completed, red
- time to complete form has not yet been reached, blue -
form is ready to be reported, yellow - form must be
reviewed, purple - patient underwent another HSCT and
black - death.
Conclusion: In October 2012 our goal was achieved and we
were able to update and report all 193 patients. Team work
and new efﬁcient tools allowed control of due dates and
optimization of time spent with data capturing, CRA/physi-
cian meetings and forms review. All items from all patients
will now be timely reported.326
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Background: The DFCI/BWCC HSCT program is estimated
to perform 525 transplants in 2012, and has performed
6000 transplants since inception in 1972. The quality
of this data had previously not been reviewed on a large
scale, only by smaller projects examining selected data
ﬁelds for limited patient sets. The accuracy of this data
is paramount since it is used for analysis of patient
outcomes, policy compliance and operational
considerations.
The goal of this project was to develop a comprehensive
and efﬁcient method of data validation for DFCI's internal
HSCT repository and DFCI's SCTOD data.
Methods: Fifty-nine transplant essential data ﬁelds were
selected for analysis including Day 0, Disease Status at
Transplant, Best Response, aGVHD, and cGVHD. A program
for comparing DFCI's internal repository data and DFCI's
CIBMTR data (retrieved with the Data Back to Center tool)
was designed in Microsoft Access, accounting for slight
differences in coding rules and logic. In 2011 over 200,000
individual data points were compared. The analysis was
performed in 2012 with more recent data.
Results: In 2011 the pre-HSCT and post-HSCT data sets
had overall error rates of 0.51% and 0.77%, respectively.
The pre-HSCT ﬁelds with error rates above 2% were
Diagnosis Date (2.16%), KPS (2.23%), and Reason RIC
(2.22%). The post-HSCT ﬁelds with high error rates above
2% were Cause of Death (3.27%) and Date of Death (3.94%).
All errors were corrected and areas for staff education
and codebook improvements were determined and
implemented.
In 2012 the error rates for the previous year's ﬁelds with
high error rates were Diagnosis Date (3.71%), KPS (0.80%),
Reason RIC (2.14%), Cause of Death (2.34%), and Date of Death
(1.37%) for data reported before the educational updates. The
coding accuracy improved for data reported after the
educational updates. For example, the error rates for the data
that was reported after the educational updates for the
previous year's ﬁelds with high error rates were Diagnosis
Date (0.70%), KPS (1.69%), and Reason RIC (1.67%). Very
limited post-HSCT data was available for data reported after
the educational updates.Conclusion: The pre-HSCT and post-HSCT data sets for
DFCI's internally and externally reported data had overall
percent error rates well below the HSCT Program's target
error rate of 2% or lower. When the analysis was performed
after staff education and codebook revisions, data accuracy
improved. Comparing similar data entered into different
databases is a valuable tool to correct data errors, as well as
to improve data accuracy in the future.328
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Cancer Registrars Evolving in Bone Marrow Transplant Data
Management Christine Gibson, CTR, CCRP Cancer Registrars
are well versed in the language of Cancer. CTR credentials are
given once education, training and testing is satisﬁed.
Training includes, anatomy and physiology, AJCC staging,
NAACCR (The North American Association of Central Cancer
Registries) guidelines for data capture, CDC, NCI SEER
guidelines for Hematopoietic Database, Collaborative
Staging, NCCN treatment guidelines and Commission on
Cancer guidelines. Many resources and many regulatory
bodies over see the data as we over see the data in our own
institutions. Standards of Care and comparisons are made to
assure the best possible patient experience. Diagnosis
information, pathology, molecular testing, IHC, FISH; cyto-
genetic, tumor markers and prognostic indicators are the
foundation of caner reporting. Radiology tests and surgical
interventions with histological diagnosis, dictate the stage of
cancer. Once a stage of cancer is derived; a treatment plan
can be made. Cancer treatment is captured in the cancer
registry. Chemotherapy regimens, radiation, immuno-
therapy, vaccines and bonemarrow transplant information is
abstracted into the cancer registry. Cancer Programs that are
American College of Surgeons, Commission on Cancer
approved are required to have Cancer Registries. Annual
follow up compliance is mandatory for all cancer patients in
the cancer registry. It would seem that if resources were
shared between the registries and regulators it could be
more cost effective, and provide better data capture for the
hematopoietic diseases. While many similarities exist
between the two entities there are many differences.
Continuous education is mandatory in a research environ-
ment. I have expanded my knowledge base. I have since
learned about consents, regulatory agencies, engraftment,
chimerism, acute and chronic GVHD, toxicities, infections
and the many different time lines to report. Cancer registry
background helped tremendously and working in a world
class facility with world class physicians made the transition
much easier.329
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information for quality review and outcomes analyses as HCT
evolves. Databases must have speciﬁcity yet ﬂexibility in
customizing data elements. Purchased proprietary applica-
tions are used bymany HCT programs, but are limited by lack
of cost-efﬁcient conﬁgurability for center-speciﬁc needs. We
sought to develop an HCT research application allowing
evolution for program and scientiﬁc growth without major
developmental costs. We identiﬁed 5 features essential for
a functional HCT database including: 1) Uniform data
capture; 2) Center-speciﬁc adaptability; 3) Rapid report
generation; 4) Accurate, current data; and 5) Productivity
tracking.
Between August 2010 and March 2012, our team of IT
developers, programmer analysts, data managers, and
a HCT physician planned, developed, tested, and launched
a new database “BRAIN” (Blood and Marrow Transplant
Research Analysis and Information Network). This
required assessment of essential data, mapping and
migration of data from a legacy database, and interface
creation to available center systems. Legacy data was
reviewed, standardized, and imported to BRAIN. Elec-
tronic interfaces connect institutional systems including
lab results and medications via the Mofﬁtt data ware-
house to BRAIN. Additionally, discrete data such as
staging and disease prognostic factors entered by clini-
cians into the electronic medical record interface with
BRAIN reducing potential reporting errors or missing data
elements. These interfaces, along with manual abstraction,
enhance data for center speciﬁc analyses and electronic
submission to CIBMTR via AGNIS. A dashboard identifying
data manager speciﬁc CIBMTR forms due creates a proﬁ-
cient process of tracking forms. Thus, with the advance-
ment of interfaces within the application and the
mapping of this discrete data to the CIBMTR, productivity
and accuracy are enriched. To date, two forms are
submitted to the CIBMTR via AGNIS. Continuing efforts to
map AGNIS-ready forms and development of a simple
query tool will allow further growth and functionality
within the application.
BRAIN fulﬁlls a program need for cost efﬁciently, managing
evolving data, enhancing data consistency, minimizing labor
for data entry, making data easily assessable within the
institution, and ensures current and accurate data submis-
sion to outside regulatory reporting agencies.330
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Background: It is well known that female fertility is
impaired after allogeneic stem cell transplantation (SCT),
however, more female patients become long term survives,
and wish to have children of their own. Data regarding
pregnancies and child births are scarce. The aim of this
study was to determine the proportion of female patients
obtaining documented pregnancy and motherhood
following SCT.Methods: We obtained data regarding pregnancies and
child births in consecutive female transplant recipients
from our center. The patients were treated with SCT in the
period from 1976 to 2012. Data was obtained through the
national centralized access to the patients’ medical records
including specialist treatment. Patients less than 17 years
of age at the time of analysis were excluded. In total, 161
women were included in the analysis. The median age at
SCT was 17.2 years, and 31.4 years at analysis. Of the 161
women, 24 (15%) died in the observation period, the
surviving 138 women were observed median 12.3 years
(0.5-36).
Results: Of the 161 women, 20 (12.3%) had at least one
documented pregnancy (i.e. fertile). One of the 20 women
which experienced pregnancy is dead and never gave
birth. Thirteen (8%) woman obtained motherhood: 8 had
one child, 5 had two children. All children born were
healthy. Among the women with a pregnancy, 9/20 (45%)
had non-malignant hematological disease, and 11/20 (55%)
had malignant disease, among the non-fertile women the
numbers were 36/141 (25%) and 106/141 (75%), respec-
tively (P ¼ .66). Of the woman with motherhood, 7/13
(54%) had non-malignant disease, whereas 38/148 (26%) of
the remaining women had non-malignant disease (P ¼
0,029).
Total body irradiation (TBI) was given to 7 (54%) of the
women with completed delivery, at a dosage of 200 cGy in 2
and 850-1200 cGy in 5 patients.
The median age at HSCT was not different among fertile
and non-fertile women, 18.6 (2.3-33) years and 16.7 (0,2-
34,6) years respectively (P ¼ .91).
Among evaluable patients, chronic graft versus host
disease (GvHD) was documented in 4/18 (22%) of the fertile
women, and 43/116 (37%) of the non-fertile women, P ¼
0,22.
Conclusion: Not all women are infertile following alloge-
neic SCT, despite treatment with TBI chemotherapy and
chronic GvHD. However, only 8% obtained motherhood,
emphasizing the need for fertility conservation proce-
dures. The current study beneﬁts from centralized access
to patient information ensuring a high quality of accurate
and complete data.331
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The number of hematopoietic cell transplants (HCT) for
Medicare beneﬁciaries has dramatically increased, height-
ening the need to address Medicare coverage and reim-
bursement. Previous analysis of CMS claims data by ASBMT
and NMDP suggested variability by HCT programs (HCTP) in
coding and billing. Addressing these issues may be critical to
ensure ﬁnancial solvency for HCTP and continued HCT access
for Medicare beneﬁciaries.
